Sulfonylureas, Insulin increase heart disease risk in diabetes : JAMA Medha Baranwal Baranwal23 Dec 2018 8:10 PM ISTChicago, Illinois: Two drugs — sulfonylureas and basal insulin -- commonly prescribed as second-line antidiabetic medication therapy, carry a high...
Use SGLT 2 Inhibitors, GLP-1 receptor agonists as first-line treatment for patients with diabetes and CVD: ESC 2019 Update Medha Baranwal Baranwal31 Aug 2019 3:17 PM ISTGLP-1 receptor agonists and gliflozins (SGLT 2 Inhibitors) should be used as first-line treatment for blood sugar control in type 2 diabetes patients...
Understanding ESC Guidelines 2019 on Diabetes In Indian Scenario with Dr Upendra Kaul Deepanjana Sarkar6 Sept 2019 7:02 PM ISTNew Delhi: The recently held European Society of Cardiology (ESC) congress 2019, saw a lot of practice-changing recommendations being made in the...
Oral semaglutide bests empagliflozin in reducing weight and HbA1c in diabetes Medha Baranwal Baranwal1 Nov 2019 8:28 PM ISTDelhi: Oral semaglutide, glucagon-like peptide 1 (GLP-1) analog, outperformed sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin in...
GLP-1 receptor agonist Dulaglutide cuts cardiovascular and kidney risk in diabetics, finds international study Hina Zahid10 Jun 2019 8:28 PM ISTOne of the longest ever study spanning over more than five years has found benefits of a cardiovascular risk-reducing agent in the field of diabetes....
These antidiabetic drugs may lead to bile duct cancer Medha Baranwal Baranwal9 Dec 2018 8:28 PM ISTCanada: DPP-4 inhibitors and GLP-1 receptor agonists, used for the treatment of type 2 diabetes (T2D), are associated with an increased risk of...
